Unknown

Dataset Information

0

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

ABSTRACT: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.

SUBMITTER: Boggs DL 

PROVIDER: S-EPMC3268840 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Boggs Douglas L DL   Kelly Deanna L DL   McMahon Robert P RP   Gold James M JM   Gorelick David A DA   Linthicum Jared J   Conley Robert R RR   Liu Fang F   Waltz James J   Huestis Marilyn A MA   Buchanan Robert W RW  

Schizophrenia research 20111203 2-3

<h4>Objective</h4>To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.<h4>Methods</h4>Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.<h4>Results</h4>In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score.  ...[more]

Similar Datasets

Unknown Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.
| S-EPMC5912319 | biostudies-literature
Unknown Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
| S-EPMC4753610 | biostudies-literature
Unknown Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study.
| S-EPMC8361730 | biostudies-literature
Unknown Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia.
| S-EPMC5547865 | biostudies-other
Unknown Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial.
| S-EPMC4848251 | biostudies-literature
Unknown Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
| S-EPMC4954262 | biostudies-literature
Unknown Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study.
| S-EPMC4576018 | biostudies-literature
Unknown Effect of Korean Red Ginseng in individuals exposed to high stress levels: a 6-week, double-blind, randomized, placebo-controlled trial.
| S-EPMC6606819 | biostudies-other
Unknown Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
| S-EPMC5156367 | biostudies-literature
Unknown A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
| S-EPMC3335844 | biostudies-literature